BioLife Solutions (BLFS) Misses Q2 EPS by 2c
Get Alerts BLFS Hot Sheet
Financial Fact:
Amortization of deferred financing costs: 0
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
BioLife Solutions (NASDAQ: BLFS) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.56 million versus the consensus estimate of $2.48 million.
Guidance:
Management reaffirms the full-year revenue guidance for biopreservation media products, which is expected to grow between 20 - 25% over 2016, with revenue for 2017 in excess of $10 million.
Based on the financial results for the six months ended June 30th, 2017, management has revised the balance of our full-year 2017 guidance as follows:
- Gross Margin for 2017 is now expected to be between 58% to 62%, which is up from the previously provided range of 55% to 60%.
- Annual operating expenses are expected to be between $8 to $8.5 million, which is down from the previous range of $8 to $9 million.
- Positive adjusted EBITDA is now expected for the full-year of 2017.
For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
- Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share